Email Sign Up
  • Home
  • About Us
    • Anatara Overview
    • Board of Directors
    • Our Team
    • Advisory Boards
  • Clinical Trials
    • Irritable Bowel Syndrome
    • Psychological Health
  • Products and Pipeline
    • Human Applications
    • Irritable Bowel Syndrome
    • Inflammatory Bowel Disease
    • Animal Applications
    • Partnering
  • Investor Centre
    • Investors Home
    • Corporate Factsheet
    • Annual Reports
    • ASX Announcements
    • Analysts’ Reports
    • Financial Reports
    • Presentations
    • Events
    • Corporate Governance
    • Corporate Directory
  • Media Centre
    • Top Stories
    • Media Coverage
    • Multimedia Gallery
    • Anatara e-news
    • Industry Links
    • Media Contacts
  • Contact
    • Contact Us
    • Subscribe for Email Alerts
  • Home
  • About Us
    • Anatara Overview
    • Board of Directors
    • Our Team
    • Advisory Boards
  • Clinical Trials
    • Irritable Bowel Syndrome
    • Psychological Health
  • Products and Pipeline
    • Human Applications
    • Irritable Bowel Syndrome
    • Inflammatory Bowel Disease
    • Animal Applications
    • Partnering
  • Investor Centre
    • Investors Home
    • Corporate Factsheet
    • Annual Reports
    • ASX Announcements
    • Analysts’ Reports
    • Financial Reports
    • Presentations
    • Events
    • Corporate Governance
    • Corporate Directory
  • Media Centre
    • Top Stories
    • Media Coverage
    • Multimedia Gallery
    • Anatara e-news
    • Industry Links
    • Media Contacts
  • Contact
    • Contact Us
    • Subscribe for Email Alerts
Home > Investor Centre > Corporate Governance

Corporate Governance

The Anatara Board strongly supports the principles of corporate governance and is committed to maintaining the highest standards within the company.

Anatara’s key charters and policies associated with our corporate governance practices are available for download below

  • Core Values
  • Constitution
  • Corporate Governance Statement
  • Corporate Governance Charter (including Audit & Risk Committee Charter)
  • Remuneration and Nomination Committee Charter

Company Policies

  • Anti-bribery and Corruption policy
  • Code of Conduct policy
  • Continuous disclosure policy
  • Diversity policy
  • Privacy policy
  • Securities trading policy
  • Securityholder Communications Policy
  • Social Media Code of Conduct policy
  • Whistleblower policy

 

In this section

  • Investors Home
  • Corporate Factsheet
  • Annual Reports
  • ASX Announcements
  • Analysts’ Reports
  • Financial Reports
  • Presentations
  • Events
  • Corporate Governance
  • Corporate Directory
  • Home
  • About Us
    • Anatara Overview
    • Board of Directors
    • Our Team
    • Advisory Boards
  • Clinical Trials
    • Irritable Bowel Syndrome
    • Psychological Health
  • Products and Pipeline
    • Human Applications
    • Irritable Bowel Syndrome
    • Inflammatory Bowel Disease
    • Animal Applications
    • Partnering
  • Investor Centre
    • Investors Home
    • Corporate Factsheet
    • Annual Reports
    • ASX Announcements
    • Analysts’ Reports
    • Financial Reports
    • Presentations
    • Events
    • Corporate Governance
    • Corporate Directory
  • Media Centre
    • Top Stories
    • Media Coverage
    • Multimedia Gallery
    • Anatara e-news
    • Industry Links
    • Media Contacts
  • Contact
    • Contact Us
    • Subscribe for Email Alerts
Email Sign Up
© 2022 Anatara Lifesciences Ltd | Privacy